Real World Outcomes and Predictive Factors of Pirtobrutinib in Mantle Cell Lymphoma After Failure of Covalent Bruton Tyrosine Kinase Inhibitors
This multi-center retrospective study of 213 mantle cell lymphoma patients who failed covalent BTK inhibitors reveals that while pirtobrutinib yields modest outcomes as a non-bridging therapy (34% ORR, 5.3-month median PFS) and is influenced by factors like short prior cBTKi exposure and TP53 mutations, it demonstrates significant efficacy as a bridging therapy for 75% of patients proceeding to CAR-T or allogeneic transplant.